Pharmaceutical composition for the management of tumors

• US 7,655,678 B2
• Filed: 11/29/2005
• Issued: 02/02/2010
• Est. Priority Date: 11/30/2004
• Status: Active Grant

• Current Assignee: Council of Scientific & Industrial Research
• Original Assignee: Council of Scientific & Industrial Research
• Inventors: Singh, Jaya, Gupta, Krishna Prabha
• Primary Examiner(s): Hartley; Michael G
• Assistant Examiner(s): Gembeh; Shirley V
• Application Number:
  US11/288,968
• Publication Number:
  US 20060281793A1
• Time in Patent Office: 1,526 Days
• Field of Search: 514/356, 514/557
• US Class Current: 514/356
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides

Abstract

The present invention relates to the effect of naturally occurring compounds on tumor development. As an example of proof, we used low; non-toxic doses of three compound e.g. Calcium D-glucarate, a naturally occurring Ca⁺⁺ salt of D-glucaric acid; Nicotinamide (NA), a naturally occurring vitamin and butyric acid (BA), a naturally occurring saturated short chain fatty acid. 7,12 dimethylbenzanthracene (DMBA), which is a very potent skin carcinogen and is an environmental pollutant, was used for skin tumor development. Experiment was performed up to 30 weeks. All the above-mentioned compounds were used either alone or concomitantly any two or all the three. In the positive control group 100% tumorigenesis was attained in 28 weeks, use of single compound led to the inhibition of DMBA induced tumorigenesis between 33 to 47%, use of two compounds resulted in the 73 to 80% reduction in tumorigenesis but the concomitant use of three compounds resulted into 100% inhibition of tumor development at the end of 30 weeks. This led us to conclude that the concomitant use of Cag, NA and BA in combination of two is useful for preventing skin tumor development for a sort or long period of time. But the concomitant use of all the three compounds, as described, exhibited the perfect synergistic effect in preventing the tumor development completely. This strategy should be equally effective in the management of benign and possibly malignant tumor in any organ caused by any mean.

Claims

1. A pharmaceutical composition for the management of skin tumors comprising calcium glucarate, nicotinamide, and butyric acid in combination with pharmaceutically acceptable excipients, diluents or carriers.

2. A composition as claimed in claim 1, comprising about 0.05 mg to about 20 mg calcium glucarate, about 0.05 mg to about 20 mg nicotinamide and about 25 μ

moles to about 500 μ

moles butyric acid.

3. A composition as claimed in claim 1, comprising about 6.0 mg calcium glucarate, about 6.0 mg nicotinamide, and about 200 μ

moles butyric acid.

4. A composition as claimed in claim 1, wherein the composition is administered topically.

5. A composition as claimed in claim 1, wherein the composition is in the form of a cream, a milk, a pomade, a salve, an impregnated pad, a gel, a spray, or a lotion.